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SUMMARY
Background—Patients with hepatitis C viral (HCV) may perceive barriers to accessing
speciality care for HCV, and these barriers may be related to depressive symptoms.
Aim—To evaluate the relationship between barriers to care, demographics, and depressive
symptoms.
Methods—A cross-sectional analysis of 126 patients referred for HCV at two speciality HCV
clinics. Barriers to care, depressive symptoms and sociodemographics were measured using
standardized instruments. A retrospective chart review was conducted to collect clinical outcome
data.
Results—Depressive symptoms were reported in 26%. Common barriers included lack of
personal financial resources; lack of HCV knowledge in the community; lack of professionals
competent in HCV care; stigmatization of HCV; and long distances to clinics offering care. After
we controlled for sociodemographics, depression accounted for an additional 7–18% of variability
in all barriers (all p values <0.01). Lower depression, marital and employment status were
associated with subsequent receipt of HCV treatment in 38% (45/120) of patients; perceived
barriers were not.
Conclusions—Depression is independently associated with perceived barriers to care. Higher
depressive scores, but not perceived barriers, were associated with nontreatment. Healthcare
providers who diagnose HCV need to be cognizant of numerous perceived barriers to accessing
HCV care, and the impact that depression may have on these perceptions and receipt of treatment.
INTRODUCTION
Chronic hepatitis C viral (HCV) infection is a silent epidemic in the US with almost 4
million Americans estimated to be infected,1 which is four times the prevalence rate of HIV/
AIDS.2 HCV-related cirrhosis and hepatocellular carcinoma are expected to double or triple
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in the next two decades.3 Fortunately, health benefits and risk reduction can be gained by
undergoing the current antiviral regimen of pegylated interferon alpha and ribavirin for 24 or
48 weeks, with chances of sustained virological response in 40–80% of treated patients.4
These eradication rates will probably improve in the next few years with the advent of triple
therapy.5, 6 Viral clearance of HCV may, in turn, reduce subsequent complications of
advanced liver disease.7, 8
Barriers to accessing medical care for HCV have been receiving more attention in the last
few years, with the realization that only a small proportion of individuals infected with HCV
undergo antiviral treatment.9, 10 However, barriers to hepatitis C medical care are probably
quite similar to the barriers which exist among other medically ill populations, especially
persons infected with HIV/AIDS.11-13 Barriers to HCV treatment may occur at the patient,
provider and healthcare system levels. Patient barriers include the ability to navigate the
healthcare system; cost of health services and treatment; lack of insurance and personal
financial resources; lack of access to mental health or substance abuse services; social
marginalization and stigma; negative experiences with the healthcare system and providers;
lack of patient knowledge; occupational concerns; fear of drug or alcohol relapse; and
unstable family or social circumstances.13-20 Providers also experience barriers to delivering
high quality HCV care, including patient non-adherence to clinic visits; concomitant HIV or
other medical comorbidities; lack of adequate training and staffing to treat patients with co-
morbid substance use or mental health disorders; and the challenging side effect profile of
the antiviral regimen.13-20 Thus, HCV patients may face myriad barriers and challenges to
accessing specialized HCV care required to treat this potentially life-threatening disease.
In addition to the aforementioned barriers, another oft-cited barrier to antiviral treatment for
patients and providers alike are co-occurring depressive symptoms. One-fourth of patients
with HCV meet DSM-IV diagnostic criteria for major depressive disorder, while 45–60% of
patients endorse some level (mild-to-severe) of depressive symptomatology.21-26 As
depression is often under-recognized and under-diagnosed, the co-morbid depression in
many HCV patients may go untreated, and unstable depression is a contraindication to
antiviral therapy.19, 27 Depression is associated with poor self-efficacy, will to function, low
self-esteem, low self-worth, reduced motivation, reduced adherence, lack of or poor social
support, greater perceived stigmatization, pessimism, hopelessness and reluctance to seek
healthcare services.28-32 These components of depressed mood are known to disrupt a broad
spectrum of health-related, proactive behaviours.32 Depression also reduces access to
general medical care because depressed patients often perceive minimal benefits from most
medical treatments.28 These cognitive and behavioural correlates of depression may be
particularly detrimental to HCV patients if depressed mood is associated with the perception
of insurmountable obstacles to accessing speciality care for HCV.
To our knowledge, no study has explored the relationship between patients’ perceptions of
barriers to speciality hepatitis care and depressive symptomatology among those infected
with HCV. We hypothesized that perceived barriers to speciality care for HCV are prevalent
and associated with depressive symptoms among persons living with HCV, over and above
relevant sociodemographic factors.
The aims of the present study were as follows:
i. To determine the most common perceived barriers to speciality care for HCV.
ii. To assess the bivariate relationships between sociodemographic factors, barriers to
care, and depressive symptoms.
iii. To determine if depressive symptoms are associated with perceived barriers to care,
after controlling for relevant sociodemographic factors.
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iv. To evaluate the relationship between barriers to care and depressive symptoms with
subsequent clinical outcomes such as commencement and completion of antiviral
treatment. (Investigation of subsequent clinical outcomes recommended by journal
reviewers.)
MATERIALS AND METHODS
Overview of study design
The primary analysis for this study was based on cross-sectional survey data from 126
participants referred for speciality hepatitis care over a 2-year period from 2004 to 2006. A
retrospective chart review was undertaken in 2010 to collect subsequent clinical outcome
data. These studies were approved by the UNC Institutional Review Board.
Participants
A total of 247 patients were approached to participate in this cross-sectional survey study.
Forty patients declined participation, and data on the variables of interest (i.e. barriers and
depression) were incomplete for 81 patients. Therefore, the cross-sectional analysis was
based on data collected from 126 participants. Inclusion criteria included a confirmed
diagnosis of HCV and new referral to one of the two hepatology clinic sites. Exclusion
criteria included a diagnosis of HIV or hepatitis B, and non-English speaking patients. All
patients who met criteria for the study were screened by the hepatology clinicians and
research assistant during the first or second visit to the clinic.
Setting
Patients were recruited, screened and informed consent was obtained at two speciality
hepatology clinics: an out-patient clinic in an academic medical centre (n = 72), and a
community-based outreach hepatology clinic (n = 54) affiliated to another healthcare
system. At the time of recruitment, these sites were staffed by the same hepatology
clinicians (two attending hepatologists; two mid-level providers).
Procedure
Patients were recruited, consent was obtained and they were assured confidentiality of the
self-administered surveys by a research coordinator. A pen and paper literacy questionnaire
was administered prior to completion of computer-based surveys to identify participants in
need of reading assistance. Participants were provided instruction on the use of computer
tablets with touch screen capabilities, and surveys were completed on the tablet computers
during the patients’ visit.
A post hoc retrospective chart review was conducted to gather subsequent clinical outcome
data on the 126 participants. At least some data were available on 120 of the 126
participants. Medical records were reviewed from the time of cross-sectional data collection
until April 2010 for the following information: (i) time (in years) from HCV diagnosis to
presentation in the speciality hepatology clinics; (ii) receipt of antiviral treatment; and for
those who commenced therapy, (iii) treatment completion, virological response, and reasons
for premature treatment discontinuation.
Measures
Depression was measured using the 10-item Center for Epidemiological Studies-Depression
(CES-D) Scale.33, 34 The CES-D has been used to assess depressive symptoms in the HCV
population.35, 36 Depressive symptoms are rated on a four-point Likert scale ranging from 0
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(‘Rarely’) to 3 (‘Most of the Time’). Scores range from 0 to 30, with a score of 10 or greater
generally considered in the depressed range.
The Sociodemographic Survey assessed gender, age, marital status, race, education level,
employment status, annual household income, insurance status, travel time to clinic and
means of transportation to clinic. With the exception of age, all variables were
dichotomized.
The Barriers to Care Scale (BACS) is a 12-item scale originally developed for HIV patients
and modified for the current study with HCV patients (16). Participants rated the extent to
which each item was perceived as a barrier to speciality care for HCV. A four-point Likert
scale was used: 1 (No problem at all), 2 (Very slight problem), 3 (Somewhat of a problem),
and 4 (Major problem). The 12 items are collapsed into four subscales:
i. Geography/Distance to HCV clinic (two items): Long distances to HCV facilities
and personnel; lack of transportation to access the HCV services needed.
ii. Medical/psychological services (four items): Medical personnel who decline to
provide direct care to persons infected with HCV; lack of healthcare professionals
who are adequately trained and competent in HCV treatment; a shortage of
psychologists, social workers, and mental health counsellors who can address
mental health issues; lack of psychological support groups for person infected with
HCV.
iii. Community stigma (two items): The level of knowledge about HCV among
citizens in the community; community residents’ stigma against persons infected
with HCV.
iv. Personal resources (four items): Lack of employment opportunities for people
infected with HCV; lack of supportive and understanding work environments for
people infected with HCV; lack of personal and financial resources; lack of
adequate and affordable housing.
Statistical analyses
Means and standard deviations (s.d.) or proportions were calculated for all independent
variables. Site differences were assessed using two-sample t-tests (continuous variables) or
chi-square tests of association (categorical variables). Bivariate associations between the
four BACS subscales (continuous variables), CES-D depressive scores (continuous
variables), and sociodemographic factors were evaluated using Pearson’s correlation for
continuous variables or two-sample t-tests for categorical variables. Each of the four
subscales was an outcome of interest and thus analysed as a dependent variable using
multiple linear regression models. For the regression models, the bivariate associations were
used for model reduction purposes and to preserve degrees of freedom. Hence, only
sociodemographic variables with a P ≤ 0.20 were included in the regression models. The
additional amount of variability in mean BACS subscale measures, explained by the
depression score after controlling for relevant sociodemographic factors and site, was
assessed using the change in R2. For clinical outcomes collected via chart extraction, time
from HCV diagnosis to presentation in clinic was based on data available for 76 of the
original 126, and treatment outcomes were based on 45 of the available 120 who underwent
antiviral treatment. Only descriptive data were presented for the subgroup of 45 treated
patients as the sample size was small. All significance levels were set at P < 0.05. All
analyses were conducted using SAS version 9.1 (SAS, Cary, NC, USA) and SPSS version
15.0 (SPSS, Chicago, IL, USA).
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There were no significant differences between patients who refused to participate in the
study (n = 40), and participants with missing barriers and depression data who were
excluded from the current analysis (n = 81). These groups were combined (nonparticipants =
121). When compared with participants in this study (n = 126), nonparticipants did not differ
on age, gender, marital status and insurance coverage. However, there were significantly
more Caucasians among the participants than nonparticipants (83% vs. 58%; P < 0.01), and
participants had higher educational attainment compared with nonparticipants (55% vs. 41%
with more than high school; P = 0.03).
Sociodemographic characteristics
When the two clinic sites were compared, we found that participants attending the academic
medical centre at the state hospital had higher rates of being uninsured (17%) compared with
those who attended the community-based clinic (4%; P = 0.04), and more participants
attending the academic medical centre travelled >1 h to clinic (49%), compared with
patients who attended the community-based clinic (2%; P < 0.01). These were the only
significant differences in sociodemographic characteristics between sites; the
sociodemographic data for the combined sample (n = 126) are presented in Table 1.
Retrospective data collection revealed that 66% (68/103) of participants had current or
lifetime illicit substance use, 50% (52/104) reported symptoms suggestive of alcohol abuse
or dependence, and 50% (53/107) reported current or lifetime psychiatric disturbances. Of
the 76 participants with available data, time from HCV diagnosis to presentation varied
greatly. Participants who had undergone interferon-based therapy previously at another
clinic (n = 15) presented at the speciality clinic 7.7 years (s.d. = 5.3 years) after HCV
diagnosis, whereas treatment-naïve participants (n = 61) presented 3.7 years (s.d. = 5.1
years) after HCV diagnosis (P < 0.01). Barriers to care subscales, depressive symptoms and
sociodemographic factors were not significantly associated with the number of years from
HCV diagnosis to presentation in the speciality clinics (data not shown).
Perceived barriers to care responses
Figure 1 provides the percentage of the 12 individual barrier items perceived as ‘no
problem’, ‘a very slight problem’, ‘somewhat of a problem’ and ‘a major problem’. When
we combined the endorsement of an item as ‘somewhat of a problem’ or a ‘major problem’,
the greatest barriers were as follows: lack of personal financial resources (50%); lack of
HCV knowledge in the community (48%); lack of professionals competent in HCV care
(33%); feeling stigmatized for having HCV (32%); and long distances to a treatment facility
(30%). Long distances to a treatment facility was the only barrier significantly different
between the two clinic sites, with 40% of patients who attended the academic medical centre
endorsing this barrier as problematic, compared to 17% of patients who attended the
satellite, community-based clinic (P < 0.01).
Bivariate associations between barriers, depression, and sociodemographic
characteristics
As shown in Table 2, Distance to an HCV clinic was perceived as a barrier in patients who
did not have self-transportation (P = 0.01). Personal and financial resources as a barrier was
associated with being unmarried (P < 0.01), having an annual household income of <$40
000 (P < 0.01), being unemployed or not working (P < 0.01), being uninsured (P = 0.04)
and not having self-transportation (P < 0.01). No sociodemographic factors were
significantly associated with the BACS subscales Lack of Medical/Psychological Services
or Community Stigma. Additionally, participants experiencing higher CES-D depression
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scores were more likely to be unmarried (P < 0.01), unemployed (P < 0.01) and report less
income (P < 0.01).
Associations between barriers to care and depression
Higher depression scores were positively correlated with all four barriers to care subscales
(Table 2). Results from the multiple regression models using the four BACS subscales as
dependent variables are presented in Table 3 and provide further support to the relationship
between depression and the BACS subscales. After controlling for any important
sociodemographic factors (significant at P ≤ 0.20 in bivariate analyses) and clinic site
(Model 1), depression accounted for an additional 7.1% of the variance in the subscale of
Distance (P < 0.01), an additional 7.0% of the variance in the subscale of Lack of Medical
and Psychological Support (P < 0.01), an additional 7.0% of the variability in the
Community Stigma subscale (P < 0.01), and 17.6% more of the variance in the Lack of
Personal Resources subscale (P < 0.01) (Model 2).
Post hoc sensitivity analysis of association between barriers to care and depression
During model diagnostics of the regression models, we observed that the distribution of the
residuals slightly to moderately deviated from the assumption of normality. We therefore
applied a Box-Cox power transformation37 to the data to ensure all assumptions of the linear
model held; however, the transformation did not prove useful. Thus, to strengthen the
confidence of our regression model findings, we ran a post hoc sensitivity analysis to assess
the relationship between depression scores and the four BACS subscales and its strength.
We re-defined each of the BACS subscales as a dichotomous variable. An average subscale
score of 2 or less was defined as ‘a slight problem or less’, and an average score of >2 was
defined as ‘somewhat of a problem or greater’. Logistic regression models were fit to the
four new outcome measures, and the significance of the depression score was assessed after
controlling for the same sociodemographic variables as in the linear regression models.
Results indicated that after adjustment, depression scores were still significantly associated
(P < 0.05) with all four BACS subscales. In other words, the odds of having ‘somewhat of a
problem or greater’ increased with increasing CES-D score. For a clinically significant 5-
point increase in CES-D scores, the odds ratio ranged from 1.47 to 2.28 for the four
subscales. There was a 47–128% increase in the odds of having ‘somewhat of a problem or
greater’ compared with ‘a slight problem or less’ for each additional five point on the CES-
D scale.
Clinical outcomes
The retrospective analysis demonstrated that 38% of individuals (45/120) subsequently
underwent antiviral treatment after participating in the cross-sectional survey study from
2004 to 2006. Compared with the 75 patients who did not initiate antiviral therapy, the 45
patients who received treatment were significantly less depressed [mean CES-D score (s.d.):
4.2 (3.6) vs. 8.9 (6.9); P < 0.01], more likely to be married (60% vs. 41%; P = 0.05) and
more likely to be employed (85% vs. 64%; P = 0.02) during the cross-sectional study. No
BACS scales were significantly associated with receipt of antiviral treatment, but the BACS
Lack of Personal and Financial Resources subscale approached significance (P = 0.08) with
untreated patients reporting greater personal resource barriers [mean (s.d.): 2.1 (0.9)]
compared with patients who received treatment [mean (s.d.): 1.8 (0.8)].
Of the 45 patients who received antiviral treatment, 62% (28/45) completed a full course of
the prescribed regimen. Of those who did not complete treatment (n = 17), 47% (8/17) were
discontinued prematurely due to side effects, 29% (5/17) for nonresponse, 12% (2/17) for
non-adherence problems, and 12% (2/17) due to patient preference. With regard to
virological response, 60% (27/45) achieved a sustained virological response, 18% (8/45)
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were nonresponders, 18% (8/45) were relapsers at 6 months post-treatment, and 4% (2/45)
had missing data. For the eight patients who discontinued treatment prematurely due to side
effects, the side effects that lead to discontinuation were neuropsychiatric (n = 3),
gastrointestinal (n = 3), fatigue (n = 2), lab abnormalities (n = 2) and other (n = 2). Totals do
not sum to 8 as some patients had more than one side effect leading to discontinuation.
DISCUSSION
Very few individuals infected with HCV actually undergo interferon-based treatment, which
is potentially curative for 40–80% of patients treated.9, 38, 39 Thus, there is growing need to
identify barriers to HCV management and treatment which may be present at the patient,
provider, institutional and societal levels. Barrier identification is the first step in devising
solutions, such as stimulating the development of models or programmes that can overcome
barriers and increase access to potentially life-saving therapy for many infected individuals.
In the present study, patients who were newly referred for a diagnosis of HCV to two
hepatology clinics endorsed many perceived barriers to accessing speciality care for HCV.
Consistent with other reports, sociodemographic factors such as employment, income level,
insurance status and marital status were associated with perceived barriers to HCV
care.17, 40 One of the most significant findings from this study was that depressive
symptoms, which were prevalent in >25% of this sample, were independently associated
with all perceived barriers, over and above the impact of sociodemographic factors. Finally,
higher depression scores predicted lower rates of antiviral treatment utilization, and
therefore represent a patient level barrier to accessing treatment, even after these patients
ostensibly overcame initial barriers to being referred to speciality clinics which treat HCV.
Between 30% and 50% of patients surveyed perceived the following significant problems in
accessing specialized care for hepatitis C: lack of personal financial resources, knowledge
about HCV in their community, professionals who were competent to provide care for
hepatitis C, feeling stigmatized for having HCV and long distances to a clinic that treats
HCV. These findings are consistent with previous research with the hepatitis C population,
as well as other medically ill populations, including HIV. For example, the cost of health
services, lack of insurance, social stigma, and lack of adequate training and staffing to treat
HCV patients with co-morbid psychiatric disorders, are all previously described
barriers.13, 14, 20
In regression models, depressive symptoms were associated with the perception of multiple
barriers, over and above the contribution of sociodemographic characteristics. In other
medically ill populations, depression has been related to the perception of extensive barriers
to accessing medical care, and to the perception of minimal benefits from medical
treatment.28 For the larger HCV community who suffers from depressive symptoms, which
may range from 25% to 60%,21, 22 these barriers, whether they be actual or perceived, can
be detrimental if patients do not access care early in their disease stage when management
and treatment may be most effective. Although we did not assess mediating variables by
which depression may exert an effect on perceived barriers to care, it is well-documented
that depression is associated with poor self-efficacy, reduced will to function, reduced
motivation, greater perceived stigmatization, pessimism, hopelessness and reluctance to seek
healthcare services.28-32 These cognitive and behavioural correlates of depression may be
considered barriers at the patient level which probably affect the perception and health-
promoting behaviours that may be required to access specialized care for hepatitis C. For
instance, the motivation, self-efficacy, perseverance and resourcefulness needed to
overcome financial, distance and transportation obstacles may be attenuated in HCV patients
with co-morbid depression. The pessimism and hopelessness that accompany depression
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may translate into inaction and passivity about pursuing treatment for their medical
condition. Lastly, as patients with both depression and HCV often perceive lower social
support and greater social stigma about their conditions,28-31 these beliefs may enhance the
perception that there is a lack of providers willing to treat or interested in treating HCV
patients. It does not matter whether these barriers are real or imagined; patient perceptions,
attitudes and beliefs are often strong predictors of intentions and behaviours.41-43
Results of the post hoc retrospective chart review need to be viewed with caution, and are
primarily descriptive in nature, although they offer some preliminary insights into the
relationship between demographics, depressive symptoms and barriers to care on time from
diagnosis to presentation in clinic, uptake of antiviral therapy, and treatment completion
rates. Although it took 61 treatment naïve patients approximately 4 years from the time of
HCV diagnosis to attend an initial visit in a speciality HCV clinic, none of the variables
investigated (depression, perceived barriers to care, demographics) were significantly
associated with this lag time. Lack of bivariate associations could be due to small sample
size, data collection time frame and methods, or other reasons not assessed (e.g. patient
preference, ongoing alcohol abuse, normal liver enzymes). We also found that patients who
subsequently received antiviral therapy in the future were less depressed, and more likely to
be married and employed. The notion that mental health issues, such as depression, are
significant barriers to treatment is consistent with other reports.44, 45 While there was a trend
for the lack of personal and financial resources as a barrier to be negatively associated with
receipt of antiviral therapy, it does not appear that perceptions about distance to an HCV
clinic, lack of medical/psychological services, or community stigma predict subsequent
receipt of antiviral therapy. Perhaps such barriers are most relevant to patients prior to
referral to a speciality HCV clinic, wherein, these barriers may cease to exert a significant
impact on subsequent clinical outcomes. This speculation would need validation from
prospective, observational studies. Finally, 62% of patients completed a full course of the
prescribed regimen. Treatment discontinuation was due to protocol-defined termination for
viral nonresponse, and adverse side effects, the most problematic of which were
neuropsychiatric and gastrointestinal.
Healthcare providers, including primary care and other front-line referring providers, may be
able to reduce barriers and increase access to speciality HCV care through altering clinical
management strategies. It is important that providers who screen for and diagnose chronic
hepatitis C recognize that co-morbid depression is quite prevalent in this patient population
and is associated with perceived barriers and receipt of antiviral therapy. Thus, depression
should be regularly screened for, and treated if present. Referral to mental health
professionals for nonpharmacological or pharmacological treatment, is another viable
option, and may actually improve a patient’s chances of becoming eligible for antiviral
treatment. Second, it should be recognized that the cognitive (e.g. hopelessness, pessimism)
and behavioural (e.g. loss of motivation, social withdrawal) correlates of depression may
inhibit the requisite proactive, help-seeking behaviours needed to pursue specialized
hepatitis care. Depressed patients may require more direct, concrete assistance (e.g.
reminder phone calls, encouragement to attend) to follow through with a referral to a
speciality clinic. This strategy may be particularly effective in outpatient settings where
HCV is prevalent among patients (e.g. methadone clinics). Feelings of guilt and shame
regarding the mode of viral acquisition, self-blame, low self-worth and social stigma are
common in depressed HCV patients, and may also feed into the belief that they are
undeserving of medical care for HCV. Providing educational materials and encouragement
about HCV in the primary care or gastroenterological setting, increasing referrals to clinics
that treat a large number of HCV patients, and providing referral for comorbid mental health
or substance abuse, may be ways in which healthcare providers can aid in overcoming
perceived barriers and increasing access to specialized care for HCV. Finally, as personal
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and financial resources were cited as the most significant barrier to speciality care, there
may be other simple and effective solutions to increase referral and access to medical care
for HCV. For instance, public health campaigns can increase awareness among patients and
front-line referring providers about clinical trials, which can offset travel and financial
burden, as well as industry-sponsored patient assistance programmes, which defray the cost
of treatment for individuals from impoverished backgrounds. Using telehealth and web-
based strategies to assist healthcare providers practising in rural community settings to
screen, manage and treat HCV is another potential vehicle that has demonstrated promise in
reducing personal and financial barriers to accessing HCV care.46
There are several limitations of this study. First, inherent to all cross-sectional study designs,
we examined associations between variables measured at the same time point, and cannot
make inferences about causal order. As such, the relationships between the variables
examined in this study may be bi-directional or mediated by a third variable. Second, our
sample comprised patients who were already being evaluated in a speciality HCV clinic.
Thus, they had already managed to navigate the healthcare system and obtain a referral to a
speciality hepatology clinic either by their primary care provider or by a community
gastroenterologist. This circumstance may have affected our findings. For instance, it is
likely that we are understating the magnitude of barriers facing the larger HCV population;
patients with the greatest obstacles to care (e.g. active drug users) were unlikely to be
referred to speciality clinics, and therefore were unrepresented in this study. It is likely that
the rate of depression and perceived obstacles to accessing care is even higher among the
larger HCV population who are not involved in a healthcare system and not represented in
this study. Additionally, these barriers may not affect subsequent clinical outcomes once the
patient is under the care of a speciality clinic. Third, our study analysed patient perceptions
of barriers to care, and perceptions may not reflect actual barriers. Fourth, our analysis of
clinical outcomes was based on a post hoc retrospective chart review and small sample size,
thus these data are prone to more measurement errors and need to be viewed with caution.
Finally, there were some deviations from the assumptions of the linear model that could
affect the robustness of the linear regression estimates. However, the same conclusions were
attained through sensitivity analyses using logistic regression.
In sum, patients with HCV report several perceived barriers to accessing healthcare specific
to HCV at the individual, community and societal levels. Common mood disorders, such as
depression, may amplify negative perceptions about the obstacles to obtaining medical care
for HCV, although it is likely that some barriers (e.g. lack of personal and financial
resources) represent actual barriers to obtaining speciality HCV care and antiviral treatment.
As the prevalence of depressive symptoms in this population is high, it is critical that
frontline healthcare providers screen, treat, or refer for depression. It is also important to
recognize that the cognitive and behavioural correlates of depression may negatively affect
patient perceptions and the help-seeking behaviours needed to overcome obstacles in the
way of accessing specialized care for HCV.
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Table 1






Gender Male 68 (54)
Female 58 (46)
Race Caucasian 105 (83)
Non-Caucasian 21 (17)
Marital status Married 62 (50)
Non-married 62 (50)
Education High school or less 56 (45)
More than high school 68 (55)
Employment status Full-time or part-time 86 (72)
Other 34 (28)
Annual income ≤$40 000 66 (55)
>$40 000 53 (45)




≤1 h 90 (71)




Other means 25 (20)
Missing data were observed for marital status, education, and transportation to clinic (N = 124); insurance coverage (N = 122); employment status
(N = 120); annual income (N = 119).
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